TL;DR
This study reveals that the kinase MARK4 plays a critical role in regulating cardiac contractility following myocardial infarction (MI) by controlling microtubule detyrosination. Targeting MARK4 shows promise as a therapeutic strategy to improve heart function in the context of ischemic heart failure.
What Problem Does This Paper Address?
Ischemic heart disease (IHD) and subsequent heart failure are major causes of mortality worldwide. While current treatments aim to improve cardiac function, there's a significant unmet need for novel therapies that enhance cardiomyocyte contractility without the high morbidity associated with existing inotropic drugs. Microtubule detyrosination has emerged as a key regulator of cardiomyocyte contractility, particularly in failing hearts. However, the precise mechanisms controlling this process and potential therapeutic targets remained poorly understood. This paper investigates the role of MARK4, a kinase known to phosphorylate microtubule-associated proteins, in regulating microtubule detyrosination and its impact on cardiac function after MI.
Methods
The researchers employed a multi-faceted approach to investigate MARK4's role:
- Murine Models: They utilized both global MARK4 knockout mice (Mark4-/-) and cardiomyocyte-specific conditional knockout mice (Mark4cKO) to study the effects of MARK4 deficiency in vivo.
- Myocardial Infarction Model: A permanent left anterior descending (LAD) coronary artery ligation model was used to induce MI in mice.
- Echocardiography: This non-invasive technique was used to assess left ventricular ejection fraction (LVEF), a key indicator of cardiac function, at various time points post-MI.
- Cardiomyocyte Isolation and Contractility Assays: Primary cardiomyocytes were isolated and subjected to electrical stimulation to measure sarcomere shortening, contraction, and relaxation velocities.
- Biochemical Assays: Western blotting was extensively used to analyze protein levels, including MARK4, detyrosinated tubulin (dTyr-tub), MAP4 phosphorylation, VASH2, and other relevant proteins in different cellular fractions.
- Microtubule Co-sedimentation Assays: These in vitro experiments were performed to investigate the direct binding interactions between MAP4, VASH2/SVBP, and polymerized microtubules.
- Immunofluorescence and STED Microscopy: These techniques were used to visualize and quantify the localization and association of proteins, particularly VASH2 and microtubules, within cardiomyocytes.
- Genetic Manipulation: Adenovirus-mediated overexpression of Tubulin Tyrosine Ligase (TTL) and knockdown of MAP4 were employed to further probe the functional consequences of detyrosination.
- Pharmacological Inhibition: Parthenolide (PTL) was used to pharmacologically inhibit microtubule detyrosination.
Datasets
Not discussed in the paper.
Key Insights and Ideas
- MARK4 is a key regulator of cardiac function post-MI: Loss of MARK4 significantly preserves LVEF after MI, indicating a crucial role in mitigating cardiac dysfunction.
- MARK4's effect is cardiomyocyte-intrinsic: Experiments with bone marrow transplants and cardiomyocyte-specific knockouts strongly suggest that MARK4's protective role is primarily within cardiomyocytes themselves, not in hematopoietic cells.
- MARK4 controls microtubule detyrosination: The absence of MARK4 leads to reduced detyrosinated microtubules in the heart, directly linking MARK4 to this important post-translational modification.
- MARK4-MAP4 interaction is central: MARK4 phosphorylates MAP4 at specific sites (S914 and S1046 in mice), which appears to alter MAP4's interaction with microtubules.
- MAP4 phosphorylation facilitates VASH2 access: Phosphorylated MAP4, particularly at S1046, seems to detach from microtubules or change its conformation, creating space for VASH2 (a tubulin detyrosinating enzyme) to access and modify α-tubulin.
- Detyrosination impacts contractility: The study provides strong evidence that MARK4-mediated detyrosination of microtubules directly influences cardiomyocyte contractility and relaxation kinetics.
Key Results
- MARK4 deficiency preserves LVEF: Mark4-/- mice showed a remarkable preservation of LVEF (63.6% higher) one week post-MI compared to wild-type littermates, without affecting infarct size.
- Improved cardiomyocyte contractility in MARK4-deficient cells: Isolated cardiomyocytes from Mark4-/- mice exhibited significantly improved sarcomere shortening and faster contraction/relaxation velocities after MI compared to wild-type cells.
- Reduced detyrosinated microtubules in Mark4-/- hearts: Detyrosinated microtubule levels were significantly lower in whole heart extracts and isolated cardiomyocytes of Mark4-/- mice post-MI.
- MARK4 controls VASH2 localization: In vitro experiments showed that MAP4 binding to microtubules inversely correlated with VASH2 binding, suggesting MAP4 acts as a gatekeeper for VASH2 access.
- MARK4 overexpression increases VASH2 association with microtubules: Overexpressing MARK4 in cardiomyocytes led to increased VASH2 association with polymerized microtubules.
Limitations and Future Work
- Long-term effects of MARK4 inhibition: The authors suggest it would be interesting to examine if the protective effect of MARK4 inactivation is sustained long-term without harmful side effects.
- MARK4 inhibition in non-ischaemic heart failure: The potential of MARK4 inhibition to improve contractile function in non-ischaemic heart failure settings warrants investigation.
- Mechanism in preserved ejection fraction HF: The marked improvement in relaxation kinetics in MARK4-deficient hearts suggests a potential benefit in heart failure with preserved ejection fraction (HFpEF).
- Other TCPs and settings: Further research is needed to explore the differential roles of other tubulin carboxypeptidases (e.g., VASH1) and to investigate these mechanisms in other contexts, such as mitosis, where detyrosinated microtubules have known roles.
- Structural and molecular mechanisms: Deeper probing into the precise molecular and structural mechanisms by which MARK4, MAP4, and VASH2 interact to regulate microtubule detyrosination is needed.
Summary updated